Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Abiraterone + ADT vs ADT only

Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.5 [1.17, 1.92]
1 study · 1199 participants
Moderate

Abiraterone + ADT vs ADT only

Adverse events grade 3 to 5 Range of · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT leads to higher grades III to V adverse events (severe and life threatening, as per… compared with ADT alone (high certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.34 [1.22, 1.47]
1 study · 1199 participants
High